Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial

The Lancet

Volumn 382, Issue 9894, 2013, Pages 780-789

  McInnes, Iain B ^a   Kavanaugh, Arthur ^b   Gottlieb, Alice B ^c   Puig, Lluís ^d   Rahman, Proton ^e   Ritchlin, Christopher ^f   Brodmerkel, Carrie ^g   Li, Shu ^g   Wang, Yuhua ^g   Mendelsohn, Alan M ^g   Doyle, Mittie K ^h   Aelion, Jacob ⁱ   Akovbyan, Gaspar ⁱ   Andersone, Daina ⁱ   Bakulev, Audrey ⁱ   Basijokiene, Vida ⁱ   Beaulieu, Andre ⁱ   Birbara, Charles ⁱ   Boh, Erin ⁱ   Bourcier, Marc ⁱ   Braun, Jurgen ⁱ   Brzezicki, Jan ⁱ   Buchanan, Russell ⁱ   Budd, John ⁱ   Bukauskiene, Loreta ⁱ   Burnette, Michael ⁱ   Crespillo, Juan Canete ⁱ   Carey, Wayne ⁱ   Chattapadhyay, Chandra ⁱ   Chudzik, Dariusz ⁱ   Cooper, Robert ⁱ   Drescher, Edit ⁱ   Dudek, Anna ⁱ   Dutz, Jan ⁱ   El Kadi, Hisham ⁱ   Erlacher, Ludwig ⁱ   Fretzin, Scott A ⁱ   Garcia Meijide, Juan A ⁱ   George, Emmanuel ⁱ   Gilchrist, Nigel ⁱ   Gladstein, Geoffrey ⁱ   Gow, Peter ⁱ   Graninger, Winfried ⁱ   Griffin, Robert M ⁱ   Guenther, Lyn ⁱ   Gulliver, Wayne ⁱ   Hall, Stephen ⁱ   Halter, Dale G ⁱ   Hobbs, Kathryn ⁱ   Ilivanova, Elana ⁱ   Jarvinen, Pentti ⁱ   Jeka, Slawomir ⁱ   Jones, Peter ⁱ   Khraishi, Majed ⁱ   Kokhan, Muza ⁱ   Kovacs, Attila ⁱ   Kovacs, Laszlo ⁱ   Kubanov, Alexey ⁱ   Kunynetz, Rod ⁱ   Langley, Richard ⁱ   Lee, Susan ⁱ   Leonardi, Craig L ⁱ   Lessard, Clode ⁱ   Lietuvininkiene, Virginija ⁱ   Lizzul, Paul ⁱ   Martin, Alan ⁱ   Maslyanskiy, Alexey ⁱ   Matheson, Robert T ⁱ   Mikazane, Helene ⁱ   Murphy, Frederick T ⁱ   Nash, Peter ⁱ   Nasonov, Eugeny ⁱ   Sarabia, Frederico Navarro ⁱ   Orlov Morozov, Alexander ⁱ   Paimela, Leena ⁱ   Palmer, William ⁱ   Papp, Kim ⁱ   Pileckyte, Margarita ⁱ   Poor, Gyula ⁱ   Poulin, Yves ⁱ   Silva, Ruben Queiro ⁱ   Rapoport, Ronald ⁱ   Rebrov, Audrey ⁱ   Rell Bakalarska, Maria ⁱ   Rich, Phoebe ⁱ   Rischmueller, Maureen ⁱ   Rojkovich, Bernadette ⁱ   Rosen, Cheryl ⁱ   Rosoph, Les ⁱ   Scheinecker, Clemens ⁱ   Schopf, Rudolph ⁱ   Sebastian, Michael ⁱ   Seigel, Stuart ⁱ   Shaikh, Saeed ⁱ   Sheeran, Tom ⁱ   Shergy, William J ⁱ   Shirinsky, Valery ⁱ   Siegel, Evan L ⁱ   Sofen, Howard ⁱ   Sterry, Wolfram ⁱ   Supronik, Jerzy ⁱ   Szabo, Zoltan ⁱ   Szanyo, Ferenc ⁱ   Tahir, Hasan ⁱ   Tan, Jerry ⁱ   Taylor, William ⁱ   Temnikov, Vadim ⁱ   Thaci, Diamant ⁱ   Toth, Darryl ⁱ   Újfalussy, Ilona ⁱ   Valleala, Heikki ⁱ   Vender, Ronald ⁱ   Wasel, Norman ⁱ   Willans, Martin ⁱ   Wollenhaupt, Jurgen ⁱ   Zamani, Omid ⁱ   Zanetakis, Ellen ⁱ   Zonova, Elena ⁱ   Zoschke, David ⁱ   Zubrzycka Sienkiewicz, Anna ⁱ   more..

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c TUFTS MEDICAL CENTER   (United States)

^d UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^e MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

^f UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^g JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^h ALEXION PHARMACEUTICALS   (United States)

ⁱ NONE

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CORTICOSTEROID; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; USTEKINUMAB;

ABSCESS; ACUTE KIDNEY FAILURE; ADULT; ANAPHYLAXIS; ARTICLE; CEREBROVASCULAR ACCIDENT; CHOLECYSTITIS; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DIARRHEA; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FATALITY; DRUG INDUCED HEADACHE; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; ERYSIPELAS; ERYTHRODERMIC PSORIASIS; FEMALE; HEART INFARCTION; HUMAN; INFECTION; INJECTION SITE REACTION; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MULTICENTER STUDY; NAUSEA; OPPORTUNISTIC INFECTION; PHARYNGOLARYNGEAL ABSCESS; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PSORIASIS AREA AND SEVERITY INDEX; PSORIATIC ARTHRITIS; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SALPINGITIS; SERUM SICKNESS; SHORT FORM 36; TUBERCULOSIS; UPPER RESPIRATORY TRACT INFECTION;

EID: 84883134297     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(13)60594-2     Document Type: Article

References (41)

1. Gladman DD, Antoni C, Mease P, Clegg DO, Nash P. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis 2005; 64 (suppl 2): ii14-17.
2. Leonard DG, O'Duffy JD, Rogers RS. Prospective analysis of psoriatic arthritis in patients hospitalized for psoriasis. Mayo Clin Proc 1978; 53: 511-18.
3. Zachariae H. Prevalence of joint disease in patients with psoriasis: implications for therapy. Am J Clin Dermatol 2003; 4: 441-47.
4. Gladman DD, Farewell VT, Wong K, Husted J. Mortality studies in psoriatic arthritis: results from a single outpatient center. II: prognostic indicators for death. Arthritis Rheum 1998; 41: 1103-10.
5. Khraishi M, MacDonald D, Rampakakis E, Vaillancourt J, Sampalis JS. Prevalence of patient-reported comorbidities in early and established psoriatic arthritis cohorts. Clin Rheumatol 2011; 30: 877-85.
6. Sokoll KB, Helliwell PS. Comparison of disability and quality of life in rheumatoid and psoriatic arthritis. J Rheumatol 2001; 28: 1842-46.
7. Torre Alonso JC, Rodriguez Perez A, Arribas Castrillo JM, Ballina Garcia J, Riestra Noriega JL, Lopez Larrea C. Psoriatic arthritis (PA): a clinical, immunological and radiological study of 180 patients. Rheumatology (Oxford) 1991; 30: 245-50.
8. Chu TW, Tsai T-F. Psoriasis and cardiovascular comorbidities with emphasis in Asia. G Ital Dermatol Venereol 2012; 147: 189-202.
9. Wong K, Gladman DD, Husted J, Long JA, Farewell VT. Mortality studies in psoriatic arthritis: results from a single outpatient clinic. I: causes and risk of death. Arthritis Rheum 1997; 40: 1868-72.
10. Leonardi CL, Matheson R, Zachariae C, et al. Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N Engl J Med 2012; 366: 1190-99.
11. Papp KA, Leonardi C, Menter A, et al. Brodalumab, an anti-interleukin-17- receptor antibody for psoriasis. N Engl J Med 2012; 366: 1181-89.
12. Leonardi CL, Kimball AB, Papp KA, et al, for the PHOENIX 1 study investigators. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 2008; 371: 1665-74.
13. Papp KA, Langley RG, Lebwohl M, et al, for the PHOENIX 2 study investigators. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 2008; 371: 1675-84.
14. Griffiths CEM, Strober BE, van de Kerkhof P, et al, for the ACCEPT Study Group. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N Engl J Med 2010; 362: 118-28.
15. Gottlieb A, Menter A, Mendelsohn A, et al. Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial. Lancet 2009; 373: 633-40.
16. Felson DT, Anderson JJ, Boers M, et al. American College of Rheumatology: preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995; 38: 727-35.
17. Prevoo MLL, van't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LBA, van Riel PLCM. Modified disease activity scores that include twenty-eight-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995; 38: 44-48.
18. Van Riel PL, van Gestel AM, Scott DL. EULAR handbook of clinical assessments in rheumatoid arthritis.Alphen aan den Rijn: Van Zuiden Communications, 2000.
19. Wells G, Becker J-C, Teng J, et al. Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate. Ann Rheum Dis 2009; 68: 954-60.
20. Aletaha D, Landewe R, Karonitsch T, et al. Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations. Arthritis Rheum (Arthritis Care Res) 2008; 59: 1371-77.
21. Fredriksson T, Pettersson U. Severe psoriasis - oral therapy with a new retinoid. Dermatologica 1978; 157: 238-44.
22. Fries JF, Spitz P, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. Arthritis Rheum 1980; 23: 137-45.
23. Heuft-Dorenbosch L, Spoorenberg A, van Tubergen A, et al. Assessment of enthesitis in ankylosing spondylitis. Ann Rheum Dis 2003; 62: 127-32.
24. Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defi ning disease status in ankylosing spondylitis: the Bath ankylosing spondylitis disease activity index. J Rheumatol 1994; 21: 2286-91.
25. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36): conceptual framework and item selection. Med Care 1992; 30: 473-83.
26. Finlay AY, Khan GK. Dermatology life quality index (DLQI) - a simple practical measure for routine clinical use. Clin Exp Dermatol 1994; 19: 210-16.
27. Conover WJ. Practical nonparametric statistics, 2nd edn. New York: John Wiley & Sons, 1980.
28. Mease PJ, Ganguly R, Wanke L, Yu E, Singh A. How much improvement in functional status is considered important by patients with active psoriatic arthritis: applying the outcome measures in rheumatoid arthritis clinical trials (OMERACT) group guidelines. Ann Rheum Dis 2004; 63 (suppl 1): 391 (abstr).
29. Ash Z, Gaujoux-Viala C, Gossec L, et al. A systematic literature review of drug therapies for the treatment of psoriatic arthritis: current evidence and meta-analysis informing the EULAR recommendations for the management of psoriatic arthritis. Ann Rheum Dis 2012; 71: 319-26.
30. Kavanaugh A, van der Heijde D, McInnes IB, et al. Golimumab in psoriatic arthritis: one-year clinical efficacy, radiographic, and safety results from a phase III, randomized, placebo-controlled trial. Arthritis Rheum 2012; 64: 2504-17.
31. Antoni C, Krueger GG, deVlam K, et al. Infl iximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis 2005; 64: 1150-57.
32. Gossec L, Smolen JS, Gaujoux-Viala C, et al. European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies. Ann Rheum Dis 2012; 71: 4-12.
33. Krausz S, Boumans MJH, Gerlag DM, et al. A phase IIa, randomized, double-blind, placebo-controlled trial of apilimod mesylate, an interleukin-12/interleukin-23 inhibitor, in patients with rheumatoid arthritis. Arthritis Rheum 2012; 64: 1750-55.
34. Celis R, Planell N, Fernandez-Sueiro JL, et al. Synovial cytokine expression in psoriatic arthritis and associations with lymphoid neogenesis and clinical features. Arthritis Res Ther 2012; 14: R93.
35. Toichi E, Torres G, McCormick TS, et al. An anti-IL-12p40 antibody down-regulates type 1 cytokines, chemokines, and IL-12/IL-23 in psoriasis. J Immunol 2006; 177: 4917-26.
36. Liu Y, Helms C, Liao W, et al. A genome-wide association study of psoriasis and psoriatic arthritis identifies new disease loci. PLoS Genet 2008; 4: e1000041.
37. Filer C, Ho P, Smith RL, et al. Investigation of association of the IL12B and IL23R genes with psoriatic arthritis. Arthritis Rheum 2008; 58: 3705-09.
38. Murphy CA, Langrish CL, Chen Y, et al. Divergent pro- and antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation. J Exp Med 2003; 198: 1951-57.
39. Park Y, Kim HS, Ahn JY, et al. IL-12p35 promotes antibody-induced joint inflammation by activating NKT cells and suppressing TGF-β. J Immunol 2010; 185: 1476-84.
40. Sherlock JP, Joyce-Shaikh B, Turner SP, et al. IL-23 induces spondyloarthropathy by acting on ROR-γt+ CD3+CD4-CD8-entheseal resident T cells. Nature Med 2012 18: 1069-76.
41. Reich K, Papp KA, Griffiths CE, et al. An update on the long-term safety experience of ustekinumab: results from the psoriasis clinical development program with up to four years of follow-up. J Drugs Dermatol 2012; 11: 300-12.